- Home
- AAMI vs DNTH Comparison
AAMI vs DNTH Comparison
Compare AAMI & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AAMI | DNTH |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AAMI | DNTH |
|---|---|---|
| Price | $47.77 | $39.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $45.00 | ★ $68.00 |
| AVG Volume (30 Days) | 224.7K | ★ 646.6K |
| Earning Date | 02-05-2026 | 11-05-2025 |
| Dividend Yield | ★ 0.09% | N/A |
| EPS Growth | ★ 45.00 | N/A |
| EPS | ★ 2.40 | N/A |
| Revenue | ★ $559,300,000.00 | $3,078,000.00 |
| Revenue This Year | $17.23 | N/A |
| Revenue Next Year | $24.02 | N/A |
| P/E Ratio | $19.60 | ★ N/A |
| Revenue Growth | ★ 19.25 | N/A |
| 52 Week Low | $22.60 | $13.37 |
| 52 Week High | $54.99 | $45.46 |
Technical Indicators
Market Signals| Indicator | AAMI | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 53.42 | 40.52 |
| Support Level | $47.20 | $40.79 |
| Resistance Level | $49.00 | $43.40 |
| Average True Range (ATR) | 1.29 | 1.76 |
| MACD | -0.11 | -0.49 |
| Stochastic Oscillator | 46.79 | 15.89 |
Price Performance
Historical ComparisonAbout AAMI Acadian Asset Management Inc.
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.